Possible interaction between opioidergic and cholinergic systems of CA1 in cholestasis-induced amnesia in mice

Behavioural Brain Research

Volumn 228, Issue 1, 2012, Pages 116-124

  Zarrindast, Mohammad Reza ^a,b,c,d   Hoseindoost, Saereh ^f   Nasehi, Mohammad ^e  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c INSTITUTE FOR RESEARCH IN FUNDAMENTAL SCIENCES IPM   (Iran)

^d INSTITUTE FOR COGNITIVE SCIENCE STUDIES ICSS   (Iran)

^e ISLAMIC AZAD UNIVERSITY   (Iran)

^f KHARAZMI UNIVERSITY   (Iran)

Author keywords

Cholestasis; Hole bored task; Mecamylamine; Mice; Naloxone; Scopolamine; Step down task

Indexed keywords

ACETYLCHOLINE; ENDORPHIN; MECAMYLAMINE; MUSCARINIC RECEPTOR; NALOXONE; NICOTINIC RECEPTOR; OPIATE RECEPTOR; SCOPOLAMINE;

AMNESIA; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANXIETY; ARTICLE; BILE DUCT LIGATION; BODY WEIGHT; CHOLESTASIS; CHOLINERGIC SYSTEM; CONTROLLED STUDY; EXPLORATORY BEHAVIOR; HIPPOCAMPAL CA1 REGION; HIPPOCAMPUS; MALE; MEMORY CONSOLIDATION; MOUSE; NONHUMAN; PRIORITY JOURNAL;

AMNESIA; ANIMALS; ANIMALS, OUTBRED STRAINS; CA1 REGION, HIPPOCAMPAL; CHOLESTASIS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; EXPLORATORY BEHAVIOR; MALE; MECAMYLAMINE; MENTAL RECALL; MICE; MICROINJECTIONS; MUSCARINIC ANTAGONISTS; NALOXONE; NICOTINIC ANTAGONISTS; RECEPTORS, OPIOID; SCOPOLAMINE HYDROBROMIDE;

EID: 83755196815     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2011.11.039     Document Type: Article

References (95)

1. Cauli O., Rodrigo R., Llansola M., Montoliu C., Monfort P., Piedrafita B., et al. Glutamatergic and gabaergic neurotransmission and neuronal circuits in hepatic encephalopathy. Metab Brain Dis 2009, 24:69-80.
2. +/bile acid cotransporter in extrahepatic cholestasis. Gastroenterology 1996, 110:199-209.
3. Stewart S.M., Campbell R.A., McCallon D., Waller D.A., Andrews W.S. Cognitive patterns in school-age children with end-stage liver disease. J Dev Behav Pediatr 1992, 13:331-338.
4. Gilberstadt S.J., Gilberstadt H., Zieve L., Buegel B., Collier R.O., McClain C.J. Psychomotor performance defects in cirrhotic patients without overt encephalopathy. Arch Intern Med 1980, 140:519-521.
5. Erceg S., Monfort P., Hernandez-Viadel M., Rodrigo R., Montoliu C., Felipo V. Oral administration of sildenafil restores learning ability in rats with hyperammonemia and with portacaval shunts. Hepatology 2005, 41:299-306.
6. Marrachelli V.G., Miranda F.J., Alabadi J.A., Llorens S., Alborch E. Contribution of endothelin receptors and cyclooxygenase-derivatives to the altered response of the rabbit renal artery to endothelin-1 in diabetes. Eur J Pharmacol 2006, 534:178-186.
7. Marquez-Aguirre A.L., Canales-Aguirre A.A., Gomez-Pinedo U., Galvez-Gastelum F.J. Molecular aspects of hepatic encephalopathy. Neurologia 2010, 25:239-247.
8. Magen I., Avraham Y., Ackerman Z., Vorobiev L., Mechoulam R., Berry E.M. Cannabidiol ameliorates cognitive and motor impairments in bile-duct ligated mice via 5-HT1A receptor activation. Br J Pharmacol 2010, 159:950-957.
9. Palomero-Gallagher N., Bidmon H.J., Cremer M., Schleicher A., Kircheis G., Reifenberger G., et al. Neurotransmitter receptor imbalances in motor cortex and basal ganglia in hepatic encephalopathy. Cell Physiol Biochem 2009, 24:291-306.
10. Mombeini T., Roushanzamir F., Jorjani M., Pourpak Z., Gaskari S.A., Mehr S.E., et al. Alteration in specific opioid-receptor labeling on peripheral blood leukocytes of bile duct-ligated rat. Pathophysiology 2006, 13:111-117.
11. Talaenko A.N., Krivobok G.K., Pankrat'ev D.V., Goncharenko N.V. Neurochemical mechanisms of dorsal pallidum in antiadverse effects of anxiolytics of different models of anxiety. Ross Fiziol Zh Im I M Sechenova 2005, 91:776-784.
12. Ebrahimkhani M.R., Kiani S., Oakley F., Kendall T., Shariftabrizi A., Tavangar S.M., et al. Naltrexone, an opioid receptor antagonist, attenuates liver fibrosis in bile duct ligated rats. Gut 2006, 55:1606-1616.
13. Garcia-Ayllon M.S., Silveyra M.X., Candela A., Compan A., Claria J., Jover R., et al. Changes in liver and plasma acetylcholinesterase in rats with cirrhosis induced by bile duct ligation. Hepatology 2006, 43:444-453.
14. Prado V.F., Martins-Silva C., de Castro B.M., Lima R.F., Barros D.M., Amaral E., et al. Mice deficient for the vesicular acetylcholine transporter are myasthenic and have deficits in object and social recognition. Neuron 2006, 51:601-612.
15. Izquierdo I., Bevilaqua L.R., Rossato J.I., Bonini J.S., Medina J.H., Cammarota M. Different molecular cascades in different sites of the brain control memory consolidation. Trends Neurosci 2006, 29:496-505.
16. Castro J.B., Urban N.N. Subthreshold glutamate release from mitral cell dendrites. J Neurosci 2009, 29:7023-7030.
17. Hagan J.J., Salamone J.D., Simpson J., Iversen S.D., Morris R.G. Place navigation in rats is impaired by lesions of medial septum and diagonal band but not nucleus basalis magnocellularis. Behav Brain Res 1988, 27:9-20.
18. Degroot A., Parent M.B. Infusions of physostigmine into the hippocampus or the entorhinal cortex attenuate avoidance retention deficits produced by intra-septal infusions of the GABA agonist muscimol. Brain Res 2001, 920:10-18.
19. Zarrindast M.R., Bakhsha A., Rostami P., Shafaghi B. Effects of intrahippocampal injection of GABAergic drugs on memory retention of passive avoidance learning in rats. J Psychopharmacol 2002, 16:313-319.
20. Bacciottini L., Passani M.B., Mannaioni P.F., Blandina P. Interactions between histaminergic and cholinergic systems in learning and memory. Behav Brain Res 2001, 124:183-194.
21. Azami K., Etminani M., Tabrizian K., Salar F., Belaran M., Hosseini A., et al. The quantitative evaluation of cholinergic markers in spatial memory improvement induced by nicotine-bucladesine combination in rats. Eur J Pharmacol 2010, 636:102-107.
22. Huerta P.T., Lisman J.E. Heightened synaptic plasticity of hippocampal CA1 neurons during a cholinergically induced rhythmic state. Nature 1993, 364:723-725.
23. Auerbach J.M., Segal M. Muscarinic receptors mediating depression and long-term potentiation in rat hippocampus. J Physiol 1996, 492(Pt 2):479-493.
24. Hasselmo M.E. Neuromodulation: acetylcholine and memory consolidation. Trends Cogn Sci 1999, 3:351-359.
25. Boyd T.E., Trepel C., Racine R.J. Cholinergic modulation of neocortical long-term potentiation in the awake, freely moving rat. Brain Res 2000, 881:28-36.
26. Okada K., Okaichi H. Functional cooperation between the hippocampal subregions and the medial septum in unreinforced and reinforced spatial memory tasks. Behav Brain Res 2010, 209:295-304.
27. Kirby B.P., Rawlins J.N. The role of the septo-hippocampal cholinergic projection in T-maze rewarded alternation. Behav Brain Res 2003, 143:41-48.
28. Moroni F., Cheney D.L., Costa E. Inhibition of acetylcholine turnover in rat hippocampus by intraseptal injections of beta-endorphin and morphine. Naunyn Schmiedebergs Arch Pharmacol 1977, 299:149-153.
29. Rezayof A., Zatali H., Haeri-Rohani A., Zarrindast M.R. Dorsal hippocampal muscarinic and nicotinic receptors are involved in mediating morphine reward. Behav Brain Res 2006, 166:281-290.
30. Zsilla G., Cheney D.L., Racagni G., Costa E. Correlation between analgesia and the decrease of acetylcholine turnover rate in cortex and hippocampus elicited by morphine, meperidine, viminol R2 and azidomorphine. J Pharmacol Exp Ther 1976, 199:662-668.
31. Imperato A., Obinu M.C., Casu M.A., Mascia M.S., Carta G., Gessa G.L. Chronic morphine increases hippocampal acetylcholine release: possible relevance in drug dependence. Eur J Pharmacol 1996, 302:21-26.
32. Khajehpour L., Rezayof A., Zarrindast M.R. Involvement of dorsal hippocampal nicotinic receptors in the effect of morphine on memory retrieval in passive avoidance task. Eur J Pharmacol 2008, 584:343-351.
33. Green J.P., Glick S.D., Crane A.M., Szilagyi P.I. Acute effects of morphine on regional brain levels of acetylcholine in mice and rats. Eur J Pharmacol 1976, 39:91-99.
34. Bergasa N.V., Alling D.W., Vergalla J., Jones E.A. Cholestasis in the male rat is associated with naloxone-reversible antinociception. J Hepatol 1994, 20:85-90.
35. Rastegar H., Homayoun H., Afifi M., Rezayat M., Dehpour A.R. Modulation of cholestasis-induced antinociception by CCK receptor agonists and antagonists. Eur Neuropsychopharmacol 2002, 12:111-118.
36. Paxinos G., Franklin K.B.J. The mouse brain in stereotaxic coordinates 2001, Academic Press. 2nd ed.
37. Zarrindast M., Madadi F., Ahmadi S. Repeated administrations of dopamine receptor agents affect lithium-induced state-dependent learning in mice. J Psychopharmacol 2009, 23:645-651.
38. Zarrindast M.R., Lahmi A., Ahamadi S. Possible involvement of mu-opioid receptors in effect of lithium on inhibitory avoidance response in mice. J Psychopharmacol 2008, 22:865-871.
39. Boissier J.R., Simon P. The exploration reaction in the mouse. Preliminary note. Therapie 1962, 17:1225-1232.
40. Rodriguez Echandia E.L., Broitman S.T., Foscolo M.R. Effect of the chronic ingestion of chlorimipramine and desipramine on the hole board response to acute stresses in male rats. Pharmacol Biochem Behav 1987, 26:207-210.
41. Vinade E.R., Schmidt A.P., Frizzo M.E., Izquierdo I., Elisabetsky E., Souza D.O. Chronically administered guanosine is anticonvulsant, amnesic and anxiolytic in mice. Brain Res 2003, 977:97-102.
42. Rezayof A., Alijanpour S., Zarrindast M.R., Rassouli Y. Ethanol state-dependent memory: involvement of dorsal hippocampal muscarinic and nicotinic receptors. Neurobiol Learn Mem 2008, 89:441-447.
43. Gholipour T., Riazi K., Noorian A.R., Jannati A., Honar H., Doratotaj B., et al. Seizure susceptibility alteration following reversible cholestasis in mice: modulation by opioids and nitric oxide. Eur J Pharmacol 2008, 580:322-328.
44. Demehri S., Samini M., Namiranian K., Rastegar H., Mehr S.E., Homayoun H., et al. Alpha 2-adrenoceptor and NO mediate the opioid subsensitivity in isolated tissues of cholestatic animals. Auton Autacoid Pharmacol 2003, 23:201-207.
45. Magen I., Avraham Y., Ackerman Z., Vorobiev L., Mechoulam R., Berry E.M. Cannabidiol ameliorates cognitive and motor impairments in mice with bile duct ligation. J Hepatol 2009, 51:528-534.
46. Kountouras J., Billing B.H., Scheuer P.J. Prolonged bile duct obstruction: a new experimental model for cirrhosis in the rat. Br J Exp Pathol 1984, 65:305-311.
47. Aronson D.C., Chamuleau R.A., Frederiks W.M., Gooszen H.G., Heijmans H.S., James J. Reversibility of cholestatic changes following experimental common bile duct obstruction: fact or fantasy. J Hepatol 1993, 18:85-95.
48. Garcia-Moreno L.M., Conejo N.M., Gonzalez-Pardo H., Aller M.A., Nava M.P., Arias J., et al. Evaluation of two experimental models of hepatic encephalopathy in rats. Braz J Med Biol Res 2005, 38:127-132.
49. Ferenci P., Lockwood A., Mullen K., Tarter R., Weissenborn K., Blei A.T. Hepatic encephalopathy-definition, nomenclature, diagnosis, and quantification: final report of the working party at the 11th World Congresses of Gastroenterology, Vienna, 1998. Hepatology 2002, 35:716-721.
50. Romero-Gomez M., Cordoba J., Jover R., del Olmo J.A., Ramirez M., Rey R., et al. Value of the critical flicker frequency in patients with minimal hepatic encephalopathy. Hepatology 2007, 45:879-885.
51. Burak K.W., Le T., Swain M.G. Increased sensitivity to the locomotor-activating effects of corticotropin-releasing hormone in cholestatic rats. Gastroenterology 2002, 122:681-688.
52. Roma M.G., Crocenzi F.A., Sanchez Pozzi E.A. Hepatocellular transport in acquired cholestasis: new insights into functional, regulatory and therapeutic aspects. Clin Sci (Lond) 2008, 114:567-588.
53. Tarter R.E., Arria A.M., Carra J., Van Thiel D.H. Memory impairments concomitant with nonalcoholic cirrhosis. Int J Neurosci 1987, 32:853-859.
54. Weissenborn K., Heidenreich S., Giewekemeyer K., Ruckert N., Hecker H. Memory function in early hepatic encephalopathy. J Hepatol 2003, 39:320-325.
55. Thomas A., Baillie G.L., Phillips A.M., Razdan R.K., Ross R.A., Pertwee R.G. Cannabidiol displays unexpectedly high potency as an antagonist of CB1 and CB2 receptor agonists in vitro. Br J Pharmacol 2007, 150:613-623.
56. Mechoulam R., Peters M., Murillo-Rodriguez E., Hanus L.O. Cannabidiol-recent advances. Chem Biodivers 2007, 4:1678-1692.
57. Iosif R.E., Ekdahl C.T., Ahlenius H., Pronk C.J., Bonde S., Kokaia Z., et al. Tumor necrosis factor receptor 1 is a negative regulator of progenitor proliferation in adult hippocampal neurogenesis. J Neurosci 2006, 26:9703-9712.
58. Barde Y.A., Edgar D., Thoenen H. Purification of a new neurotrophic factor from mammalian brain. EMBO J 1982, 1:549-553.
59. Lozeva V., Montgomery J.A., Tuomisto L., Rocheleau B., Pannunzio M., Huet P.M., et al. Increased brain serotonin turnover correlates with the degree of shunting and hyperammonemia in rats following variable portal vein stenosis. J Hepatol 2004, 40:742-748.
60. Butterworth R.F. The neurobiology of hepatic encephalopathy. Semin Liver Dis 1996, 16:235-244.
61. Bearn J., Allain T., Coskeran P., Munro N., Butler J., McGregor A., et al. Neuroendocrine responses to d-fenfluramine and insulin-induced hypoglycemia in chronic fatigue syndrome. Biol Psychiatry 1995, 37:245-252.
62. Swain M.G., Patchev V., Vergalla J., Chrousos G., Jones E.A. Suppression of hypothalamic-pituitary-adrenal axis responsiveness to stress in a rat model of acute cholestasis. J Clin Invest 1993, 91:1903-1908.
63. Forton D.M., Patel N., Prince M., Oatridge A., Hamilton G., Goldblatt J., et al. Fatigue and primary biliary cirrhosis: association of globus pallidus magnetisation transfer ratio measurements with fatigue severity and blood manganese levels. Gut 2004, 53:587-592.
64. Houghoghi V., Rezayof A., Zyaian S., Zarrindast M.R. Intradorsal hippocampal microinjection of lithium reverses morphine-induced impairment of memory in mice: interactions with dopamine receptor mechanism(s). Behav Pharmacol 2009, 20:680-687.
65. Zarrindast M.R., Navaeian M., Nasehi M. Influence of three-day morphine-treatment upon impairment of memory consolidation induced by cannabinoid infused into the dorsal hippocampus in rats. Neurosci Res 2010, 69:51-59.
66. Ghafourifar P., Dehpour A.R., Akbarloo N. Inhibition by L-NA, a nitric oxide synthase inhibitor, of naloxone-precipitated withdrawal signs in a mouse model of cholestasis. Life Sci 1997, 60:PL265-PL270.
67. Dehpour A.R., Akbarloo N., Ghafourifar P. Endogenous nitric oxide modulates naloxone-precipitated withdrawal signs in a mouse model with acute cholestasis. Behav Pharmacol 1998, 9:77-80.
68. Bergasa N.V., Rothman R.B., Vergalla J., Xu H., Swain M.G., Jones E.A. Central mu-opioid receptors are down-regulated in a rat model of cholestasis. J Hepatol 1992, 15:220-224.
69. Dehpour A.R., Sadeghipour H.R., Nowroozi A., Akbarloo N. The effect of the serotonergic system on opioid withdrawal-like syndrome in a mouse model of cholestasis. Hum Psychopharmacol 2000, 15:423-428.
70. Miller K.K., Lupica C.R. Morphine-induced excitation of pyramidal neurons is inhibited by cholecystokinin in the CA1 region of the rat hippocampal slice. J Pharmacol Exp Ther 1994, 268:753-761.
71. Azami N.S., Piri M., Oryan S., Jahanshahi M., Babapour V., Zarrindast M.R. Involvement of dorsal hippocampal alpha-adrenergic receptors in the effect of scopolamine on memory retrieval in inhibitory avoidance task. Neurobiol Learn Mem 2010, 93:455-462.
72. Bartus R.T., Dean R.L., Beer B., Lippa A.S. The cholinergic hypothesis of geriatric memory dysfunction. Science 1982, 217:408-414.
73. Freund T.F., Antal M. GABA-containing neurons in the septum control inhibitory interneurons in the hippocampus. Nature 1988, 336:170-173.
74. Gaykema R.P., Luiten P.G., Nyakas C., Traber J. Cortical projection patterns of the medial septum-diagonal band complex. J Comp Neurol 1990, 293:103-124.
75. Mesulam M.M., Mufson E.J., Wainer B.H., Levey A.I. Central cholinergic pathways in the rat: an overview based on an alternative nomenclature (Ch1-Ch6). Neuroscience 1983, 10:1185-1201.
76. Garcia-Ayllon M.S., Cauli O., Silveyra M.X., Rodrigo R., Candela A., Compan A., et al. Brain cholinergic impairment in liver failure. Brain 2008, 131:2946-2956.
77. Castellano C., Cabib S., Puglisi-Allegra S. Psychopharmacology of memory modulation: evidence for multiple interaction among neurotransmitters and hormones. Behav Brain Res 1996, 77:1-21.
78. Eidi M., Zarrindast M.R., Eidi A., Oryan S., Parivar K. Effects of histamine and cholinergic systems on memory retention of passive avoidance learning in rats. Eur J Pharmacol 2003, 465:91-96.
79. Hagan J.J., van der Heijden B., Broekkamp C.L. The relative potencies of cholinomimetics and muscarinic antagonists on the rat iris in vivo: effects of pH on potency of pirenzepine and telenzepine. Naunyn Schmiedebergs Arch Pharmacol 1988, 338:476-483.
80. Molchan S.E., Martinez R.A., Hill J.L., Weingartner H.J., Thompson K., Vitiello B., et al. Increased cognitive sensitivity to scopolamine with age and a perspective on the scopolamine model. Brain Res Brain Res Rev 1992, 17:215-226.
81. Sharma A.C., Kulkarni S.K. Effects of MK-801 and ketamine on short-term memory deficits in passive avoidance step-down task paradigm in mice. Methods Find Exp Clin Pharmacol 1991, 13:155-159.
82. Smith G. Animal models of Alzheimer's disease: experimental cholinergic denervation. Brain Res 1988, 472:103-118.
83. Fibiger H.C. Cholinergic mechanisms in learning, memory and dementia: a review of recent evidence. Trends Neurosci 1991, 14:220-223.
84. Gallagher M., Colombo P.J. Ageing: the cholinergic hypothesis of cognitive decline. Curr Opin Neurobiol 1995, 5:161-168.
85. Izquierdo I., da Cunha C., Rosat R., Jerusalinsky D., Ferreira M.B., Medina J.H. Neurotransmitter receptors involved in post-training memory processing by the amygdala, medial septum, and hippocampus of the rat. Behav Neural Biol 1992, 58:16-26.
86. Hasselmo M.E., Barkai E. Cholinergic modulation of activity-dependent synaptic plasticity in the piriform cortex and associative memory function in a network biophysical simulation. J Neurosci 1995, 15:6592-6604.
87. Hasselmo M.E. Neuromodulation and the hippocampus: memory function and dysfunction in a network simulation. Prog Brain Res 1999, 121:3-18.
88. Wheeler G.E., Coleman R., Finean J.B. Cholinesterase activities in subcellular fractions of rat liver. Association of acetylcholinesterase with the surface membrane and other properties of the enzyme. Biochim Biophys Acta 1972, 255:917-930.
89. Satler J.J., Predan S., Brzin M. The activity and cytochemical localization of acetylcholinesterase and butyrylcholinesterase in the rat liver. Histochemistry 1974, 39:65-70.
90. Perelman A., Brandan E. Different membrane-bound forms of acetylcholinesterase are present at the cell surface of hepatocytes. Eur J Biochem 1989, 182:203-207.
91. Berninsone P., Katz E., Napp M., Azcurra J. Acetylcholinesterase and nonspecific cholinesterase activities in rat liver: subcellular localization, molecular forms, and some extraction properties. Biochem Cell Biol 1989, 67:817-822.
92. Gomez J.L., Garcia-Ayllon M.S., Campoy F.J., Vidal C.J. Muscular dystrophy alters the processing of light acetylcholinesterase but not butyrylcholinesterase forms in liver of Lama2(dy) mice. J Neurosci Res 2000, 62:134-145.
93. Domino E.F., Wilson A. Effects of narcotic analgesic agonists and antagonists on rat brain acetylcholine. J Pharmacol Exp Ther 1973, 184:18-32.
94. Large W.A., Milton A.S. The effect of acute and chronic morphine administration on brain acetylcholine levels in the rat. Br J Pharmacol 1970, 38:451P-452P.
95. Richter J.A., Goldstein A. Effects of morphine and levorphanol on brain acetylcholine content in mice. J Pharmacol Exp Ther 1970, 175:685-691.